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LETTERS TO THE EDITOR
Treatment of
Pulmonary Epithelioid
Hemangioendothelioma
with Bevacizumab
To the Editor:
We read the article by Belmont
et al.1 with great interest. In the article,
the author reported that a patient with
pulmonary epithelioid hemangioendo-
thelioma (PEH) showed a good partial
response to combination chemother-
apy of carboplatin, paclitaxel, and be-
vacizumab. That was the first report of
bevacizumab for PEH, and the antitu-
mor activity shown was striking. Re-
cently, we also treated a patient with
PEH using the same regimen.
A 44-year-old woman, who had
been followed-up for bilateral pulmonary
nodules for 15 years, was referred to our
hospital because of increased size of the
nodules. Bronchofiberscopic examination
and computed tomography-guided needle
biopsy were performed; however, no def-
inite diagnosis was obtained. Finally, vid-
eo-assisted thoracoscopic surgery was
performed. Histologically, the nodules
consisted of short, single-file cords, nests,
or single cells embedded in the myxohya-
line matrix. Intracytoplasmic vacuoles
were present (Figure 1A), and the alveolar
septa were well preserved. Prominent ne-
crosis was present in the central area of
the nodule. The peripheral portion of
the tumor was more cellular than the
central portion. The tumor cells spread
into the bronchioles, vessels, and lym-
phatics. Immunohistochemical study
demonstrated that tumor cells were
positive for endothelial markers,
CD31, CD34, and factor VIII, and neg-
ative for keratin and thyroid transcrip-
tion factor-1 (Figure 1B). A diagnosis of
epithelioid hemangioendothelioma was
made. The tumor contained areas of
more nuclear atypia and mitoses at the
periphery of the nodule (Figure 1C),
suggesting more aggressive behavior of
the tumor than typical epithelioid he-
mangioendothelioma.
At the time of diagnosis, she already
had liver and bone metastases and com-
plained of lumbago arising from the me-
tastasis to the sacrum. After radiotherapy
(39 Gy) to the sacrum, she was fol-
lowed-up without chemotherapy, taking
into account the following two aspects: (1)
PEH progresses slowly in general; and (2)
there is no standard chemotherapy for
PEH; however, her disease gradually pro-
gressed and she started chemotherapy 2
years after the diagnosis.
She started combination chemo-
therapy of carboplatin and paclitaxel
concurrent with zoledronic acid for
three cycles; however, her tumor in-
creased in size. Thereafter, she received
another two cycles of chemotherapy
with carboplatin, paclitaxel, and bevaci-
zumab (15 mg/kg). Although there were
no distinct toxicities from bevacizumab,
her disease progressed and the treatment
was terminated.
Epithelioid hemangioendothelioma,
formerly known as intravascular bron-
choalveolar tumor, is a rare vascular
tumor of borderline or low-grade malig-
nancy and can arise from various or-
gans, including lung, liver, and bone.2
The biologic behavior is generally indo-
lent; however, it is highly variable. Sur-
gical resection is selected when the PEH
lesion is solitary or when the number of
lesions is limited. Although there are
isolated case reports suggesting the ef-
fectiveness of chemotherapy, no stan-
dard chemotherapy has been established
because of the rarity of this disease.3
In the article by Belmont et al., a
patient with PEH was treated with carbo-
platin, paclitaxel, and bevacizumab after
the failure of chemotherapy with cisplatin
and etoposide, and a marked response was
observed. In addition, Mascarenhas et al.4
reported the effectiveness of thalidomide,
a drug with antiangiogenic properties, for
PEH. Although no tumor response was
observed in our case, the second using
bevacizumab for PEH, treatment with an
antiangiogenic agent seems to be quite
reasonable considering that PEH is a tu-
mor of vascular origin. Further studies of
bevacizumab are needed to treat this rare
but fatal disease.
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FIGURE 1. A, Small clusters of epithelioid cells, some of which possess vacuolated
cytoplasma (arrows), are embedded in fibromyxoid matrix (hematoxylin and eosin,
original magnification 200). B, Cells are immunoreactive for endothelial marker
CD31 (original magnification 200). C, Area of prominent nuclear atypia (hema-
toxylin and eosin, original magnification 200).
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Erlotinib and
Gastrointestinal Ulcer
To the Editor:
Erlotinib is an orally available epi-
dermal growth factor receptor-tyrosine
kinase inhibitor (EGFR-TKI) and has
been used as second- or third-line
treatment for non-small cell lung can-
cer worldwide.1 It is also approved for
pancreatic cancer in combination with
gemcitabine. Its toxicities are gener-
ally mild, with the major toxicities
being skin rash, diarrhea, and liver dys-
function. Recently, however, Genentech
and OSI Pharmaceuticals have issued im-
portant safety information, stating that pa-
tients receiving concomitant antiangio-
genic agents, corticosteroids, nonsteroidal
antiinflammatory drugs (NSAIDs), and/or
taxane-based chemotherapy, or who have
a history of peptic ulceration or diverticu-
lar disease are at greater risk for develop-
ing gastrointestinal perforation.2
Between March 2008 and March
2010, 103 patients with non-small cell
lung cancer were treated with erlotinib
in our hospital. All patients started erlo-
tinib as a single agent at a dose of 150
mg/body/d. We reviewed these patients
and identified five patients who devel-
oped gastrointestinal events during the
treatment period: four patients with hem-
orrhagic gastrointestinal ulcer confirmed
by gastrointestinal endoscopy and one pa-
tient with gastrointestinal perforation.
Table 1 shows the characteristics of all
103 patients. The significance of the rela-
tionships between clinical factors and the
onset of gastrointestinal events was eval-
uated using univariate analysis with
Fisher’s exact probability test. There
were no significant associations between
age, sex, performance status, history of
peptic ulcer, and the concomitant use of
steroids and anticoagulants and gastro-
intestinal events; however, only the use
of NSAIDs was significantly associated:
all five patients had received NSAIDs
concomitantly with erlotinib in the gas-
trointestinal event () group, whereas
29 of 98 patients had received NSAIDs
in the gastrointestinal event () group.
In addition, four of five patients had not
received either H2-blockers or proton-
pump inhibitors in the gastrointestinal
event () group, whereas 18 of 29 pa-
tients had not received in the gastroin-
testinal event () group. Only one pa-
tient had received H2-blocker in the
gastrointestinal event () group; how-
ever, he had also received steroids and
developed gastrointestinal perforation.
The incidence rate of 4.9% (5 of 103)
for gastrointestinal ulcer was fairly high,
although there is no conclusive proof
that all gastrointestinal events were
caused with erlotinib; however, consid-
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TABLE 1. Patient Characteristics
Gastrointestinal Event
() n  98
Gastrointestinal Event
() (n  5) p
Age (yr)
70 64 2 0.3472
70 34 3
Sex
Male 54 4 0.3831
Female 44 1
PS
0/1 72 2 0.1342
2/3/4 26 3
Histology
Ad 83 3 0.1898
Non-Ad 15 2
Prior history of peptic ulcer
Yes 7 0 0.9999
No 91 5
Use of NSAIDs
Yes 24 5 0.0014*
No 74 0
Use of steroids
Yes 18 1 0.9999
No 80 4
Use of H2-blockers
Yes 22 1 0.9999
No 76 4
Use of PPIs
Yes 5 0 0.9999
No 93 5
Use of anticoagulants
Yes 4 1 0.2242
No 94 4
PS, performance status; Ad, adenocarcinoma; NSAIDs, nonsteroidal antiinflammatory drugs; PPI, proton-
pump inhibitor. *, statistically significant.
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